BioInvent International AB announces the enrollment of the first patient in a Phase 1/2 trial in combination with KEYTRUDA®, MSD’s anti-PD-1 therapy, investigating a subcutaneous formulation of its lead drug candidate, the novel anti-FcyRIIB antibody BI-1206, in solid tumors.
